Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1194/jlr.R053066 http://scihub22266oqcxt.onion/10.1194/jlr.R053066 C5003159!5003159 !26637277     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26637277 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Lipid+Res 2016 ; 57 (9 ): 1612-8 Nephropedia Template TP {{tp|p=26637277 |t=2016. Current therapies for lowering lipoprotein (a) |pdf=|usr=}}{{26637277 }} gab.com Text Current therapies for lowering lipoprotein (a) JO: J Lipid Res http://www.kidney.de/pget.php?&tw=1&pmid=26637277 #FOAvip Lipoprotein (a) [Lp(a)] is a human plasma lipoprotein with unique structural and functional characteristics. Lp(a) is an assembly of two components: a central core with apoB and an additional glycoprotein, called apo(a). Ever since the strong association between elevated levels of Lp(a) and an increased risk for CVD was recognized, interest in the therapeutic modulation of Lp(a) levels has increased. Here, the past and present therapies aiming to lower Lp(a) levels will be reviewed, demonstrating that these agents have had varying degrees of success. The next challenge will be to prove that Lp(a) lowering also leads to cardiovascular benefit in patients with elevated Lp(a) levels. Therefore, highly specific and potent Lp(a)-lowering strategies are awaited urgently. Twit Text FOAVip Current therapies for lowering lipoprotein (a) ????J Lipid Res http://www.kidney.de/pget.php?&tw=1&pmid=26637277 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26637277 #FOAvip English Wikipedia <ref>{{Cite pmid|26637277 }}</ref> Current therapies for lowering lipoprotein (a) #MMPMID26637277 van Capelleveen JC ; van der Valk FM ; Stroes ES J Lipid Res 2016[Sep]; 57 (9 ): 1612-8 PMID26637277 show ga Lipoprotein (a) [Lp(a)] is a human plasma lipoprotein with unique structural and functional characteristics. Lp(a) is an assembly of two components: a central core with apoB and an additional glycoprotein, called apo(a). Ever since the strong association between elevated levels of Lp(a) and an increased risk for CVD was recognized, interest in the therapeutic modulation of Lp(a) levels has increased. Here, the past and present therapies aiming to lower Lp(a) levels will be reviewed, demonstrating that these agents have had varying degrees of success. The next challenge will be to prove that Lp(a) lowering also leads to cardiovascular benefit in patients with elevated Lp(a) levels. Therefore, highly specific and potent Lp(a)-lowering strategies are awaited urgently. |Apolipoprotein B-100/*blood [MESH] |Apolipoproteins A/*blood [MESH] |Cardiovascular Diseases/blood/*drug therapy [MESH] |Humans [MESH] |Hypolipidemic Agents/therapeutic use [MESH] |Lipoprotein(a)/*blood/drug effects [MESH]Current therapies for lowering lipoprotein (a) (epmc).pdf DeepDyve Pubget Overpricing